2004
DOI: 10.1016/j.jhep.2004.05.019
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
56
0
1

Year Published

2005
2005
2015
2015

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 67 publications
(59 citation statements)
references
References 112 publications
2
56
0
1
Order By: Relevance
“…11,25,26 A meta-analysis comprising 3257 treatmentnaïve patients enrolled in 17 controlled clinical trials showed that amantadine augments the response to interferon alfa in treatment-naïve patients, albeit to a lesser extent than most clinical trials assumed for sample size calculation. 15 In the largest randomized, placebo-controlled trial, 400 treatment-naïve patients with chronic hepatitis C were enrolled. 11 Sustained virological response rates observed in patients receiving triple therapy with 200 mg amantadine per day in combination with interferon alfa induction therapy and ribavirin for 48 weeks were 52% compared with 44% in patients receiving placebo plus interferon alfa induction and ribavirin; however, the difference did not reach statistical significance.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…11,25,26 A meta-analysis comprising 3257 treatmentnaïve patients enrolled in 17 controlled clinical trials showed that amantadine augments the response to interferon alfa in treatment-naïve patients, albeit to a lesser extent than most clinical trials assumed for sample size calculation. 15 In the largest randomized, placebo-controlled trial, 400 treatment-naïve patients with chronic hepatitis C were enrolled. 11 Sustained virological response rates observed in patients receiving triple therapy with 200 mg amantadine per day in combination with interferon alfa induction therapy and ribavirin for 48 weeks were 52% compared with 44% in patients receiving placebo plus interferon alfa induction and ribavirin; however, the difference did not reach statistical significance.…”
Section: Discussionmentioning
confidence: 99%
“…[9][10][11][12][13][14] Randomized placebo-controlled multicenter clinical trials revealed controversial results for treatment-naïve patients, and meta-analyses suggested a slight improvement of sustained virological response rates for interferon-based treatment with amantadine. 15 In addition to results from clinical trials, in vitro examinations suggested inhibition of the HCV p7-protein by amantadine and an association of specific amino acid variations in the p7-protein with virological response to amantadine in combination with PEG IFN-␣ and ribavirin. [16][17][18][19] In most previous clinical trials in patients with chronic hepatitis C, amantadine was administered at a dose of 200 mg amantadine sulfate or hydrochloride per day.…”
mentioning
confidence: 99%
“…first-generation protease inhibitors), genotype dependence has commonly been cited as a reason not to pursue p7 as a viable drug target. This was fuelled by both the spectre of amantadine's failings in the treatment of influenza, combined with a lack of efficacy when prototypes such as amantadine were combined with IFN/ribavirin in clinical studies (Deltenre et al, 2004;Mangia et al, 2004;Maynard et al, 2006). Nevertheless, both rimantadine and the imino-sugar N-nonyl deoxynojirimycin (NN-DNJ) displayed broad genotype activity (Gottwein et al, 2011;Griffin et al, 2008;Steinmann et al, 2007b).…”
Section: Hcv P7mentioning
confidence: 99%
“…The current regime of pegylated interferon ␣ and ribavirin, while effective against certain viral genotypes, is largely ineffective against the most common HCV genotype 1 (1, 2) viruses making the search for new HCV anti-viral drug targets crucial. A recent metaanalysis of multiple clinical trials where amantadine was included alongside current therapies showed that an improved sustained viral response was achieved in patients that had previously failed to respond to dual therapy (3).…”
mentioning
confidence: 99%